The Federal Court granted an application to invalidate and strike out the impugned trademark registration No. TMA 1001070 (the “Impugned Registration”) pursuant to subsection 57(1) of the Trademarks Act.

This appeal by Zara Natural Stones Inc. (ZNSI) concerns an attempt to register the trademark ZARA Natural Stones & Design (a design mark).

The Federal Court granted the Plaintiff’s motion for default judgment in a trademark infringement action. The Plaintiff was also granted injunctive relief, delivery up of infringing materials, damages, and costs.

The Plaintiff, Akebia Therapeutics Inc. (“Akebia”), brought a motion requesting that the Court vacate the Defendant’s, Fibrogen Inc. (“Fibrogen”), designation of confidentiality over the entirety of two fact witness statements. The Court granted the motion on the basis that Fibrogen’s confidentiality designations were contrary to the terms of the Confidentiality Agreement between the parties.

Vincent Lam was a co-founder and former CEO of Ark Platforms Inc., which developed and marketed map-based project management software under the name “Arkit.”

This was an application seeking to vary the records of the Canadian Patent Office relating to the named inventors of Patent No. 2,508,339 [the ‘339 Patent].

This was a successful motion for leave to intervene on a default judgment motion.

NCS Multistage (NCS) appealed two Orders denying its request, on the eve of trial, to amend its pleading to: (a) include a remedy of a constructive trust; and, (b) allege that the patent infringement at issue had started earlier than originally claimed and to compel production of certain technical drawings from this earlier period. NCS’s appeal was dismissed.

This is a judicial review of the Copyright Board (the “Board”)’s decision respecting the quantum of royalty rates payable under Tariff for the Retransmission of Distant Television Signals, 2014-2018.

The Federal Court of Appeal upheld Seedlings Life Science Ventures v Pfizer Canada, 2020 FC 1, that found patent claims of an apparatus and method for rapid autoinjection (the ‘935 Patent) invalid for overbreadth, certain claims invalid for anticipation and obviousness, and not infringed (¶4, 6), and set aside the Federal Court’s conclusion that claims for an accounting of profits would be disallowed from licensees (¶77-81).